Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | AVPR2 | P30518 | 19/20 | 0.39 |
| ▸ | AVPR1A | P37288 | 19/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | OXTR | P30559 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18783447 | 1.00 | GAA (0.40) | GAAAVPR2AVPR1ASLC6A2OXTR | |
| SCHEMBL18783446 | 1.00 | GAA (0.40) | GAAAVPR2AVPR1ASLC6A2OXTR | |
| SCHEMBL27906861 | 0.77 | CNR1 (0.37) | AVPR2AVPR1AOPRK1 | |
| SCHEMBL22366250 | 0.77 | — | — | |
| SCHEMBL28027065 | 0.69 | GAA (0.36) | GAAAVPR2AVPR1A | |
| SCHEMBL21026367 | 0.68 | GAA (0.37) | GAAAVPR2AVPR1A | |
| SCHEMBL256612 | 0.68 | AVPR2 (0.51) | AVPR2AVPR1A | |
| SCHEMBL409762 | 0.68 | AVPR2 (0.51) | AVPR2AVPR1A | |
| SCHEMBL460084 | 0.68 | AVPR2 (0.51) | AVPR2AVPR1A | |
| SCHEMBL18808842 | 0.66 | AVPR2 (0.59) | AVPR2AVPR1ASLC6A2OXTROPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2619188-A1 | SUBSTITUTED N-PHENETHYLTRIAZOLONEACETAMIDES AND USE THEREOF | Bayer Intellectual Property GmbH (DE) | 2013-07-31 | — | — | EP | disclosed |
| WO-2012028644-A1 | SUBSTITUTED N-PHENETHYLTRIAZOLONEACETAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-08 | — | — | WO | disclosed |
| EP-2408754-A1 | Triazole derivatives as vasopressin-receptor inhibitors for treating cardiac insufficiency | Bayer Pharma Aktiengesellschaft (DE) | 2012-01-25 | — | — | EP | disclosed |
| WO-2010105750-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN-RECEPTOR INHIBITORS FOR TREATING CARDIAC INSUFFICIENCY | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-09-23 | — | — | WO | disclosed |
| EP-2027096-A1 | SUBSTITUTED ARYLIMIDAZ0L0NE AND TRIAZ0L0NE AS INHIBITORS OF VASOPRESSIN RECEPTORS | Bayer HealthCare AG (DE) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007134862-A1 | SUBSTITUTED ARYLIMIDAZ0L0NE AND TRIAZ0L0NE AS INHIBITORS OF VASOPRESSIN RECEPTORS | BAYER HEALTHCARE AG (DE) | 2007-11-29 | — | — | WO | disclosed |